RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

LOS ALTOS, Calif. / Jul 31, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43 Annual Canaccord Genuity Growth Conference on…Read More

Leave a Reply

Your email address will not be published. Required fields are marked *